Back to Search
Start Over
Two Tales: One Story: EMPEROR-Reduced and DAPA-HF.
- Source :
-
Circulation . 12/8/2020, Vol. 142 Issue 23, p2201-2204. 4p. - Publication Year :
- 2020
-
Abstract
- Keywords: dapagliflozin; empagliflozin; heart failure; SGLT2 inhibition EN dapagliflozin empagliflozin heart failure SGLT2 inhibition 2201 2204 4 12/10/20 20201208 NES 201208 Although the sodium-glucose cotransporter-2 (SGLT2) inhibitors were originally developed to manage hyperglycemia in people with type 2 diabetes, they have consistently been found to improve heart failure and kidney outcomes. Background therapy for HFrEF was excellent in both trials, with high rates of goal-directed medical therapy including -blockers, renin-angiotensin-aldosterone system inhibitors, and mineralocorticoid antagonists. Approximately 17% of patients discontinued therapy in EMPEROR-Reduced (versus 11% in DAPA-HF), and vital status was unknown in 21 patients in EMPEROR-Reduced (versus 2 in DAPA-HF). [Extracted from the article]
Details
- Language :
- English
- ISSN :
- 00097322
- Volume :
- 142
- Issue :
- 23
- Database :
- Academic Search Index
- Journal :
- Circulation
- Publication Type :
- Academic Journal
- Accession number :
- 147479406
- Full Text :
- https://doi.org/10.1161/CIRCULATIONAHA.120.051122